You are here
Circumvent Pharmaceuticals
UEI: Y14DQ5VD56A7
# of Employees: 4
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
Alzheimer's Disease: simultaneous modulation of NMDAR, BACE1, APP and Fyn activity by palmitoylation-targeting CIRC825
Amount: $507,284.00PROJECT SUMMARY/ABSTRACT Alzheimer’s Disease (AD) has predominantly been characterized by amyloid plaques and neurofibrillary tau tangles, and soluble oligomers of these peptides are thought to be t ...
SBIRPhase I2021Department of Health and Human Services National Institutes of Health -
Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten Disease
Amount: $304,787.00SummaryIn the Specific Aims outlined by the following proposal for an NIH SBIR Phase 1 project, we will use a multi-faceted approach to identify key substrates for targeted assay development to monito ...
STTRPhase I2021Department of Health and Human Services National Institutes of Health -
Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL)
Amount: $2,891,667.00PROJECT SUMMARY/ABSTRACT A significant unmet medical need exists for a therapy to treat patients with Infantile Neuronal Ceroid Lipofuscinosis (INCL, or CLN1 Batten Disease.) There are an estimated lt ...
SBIRPhase II2021Department of Health and Human Services National Institutes of Health -
Development of N tert Butyl hydroxylamine NtBuHA as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis INCL
Amount: $198,790.00PROJECT SUMMARY ABSTRACT There is a significant unmet medical need for a therapy to treat patients with Infantile Neuronal Ceroid Lipofuscinosis type CLN Batten Disease for which there are andlt ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health
